Bristol-Myers Squibb Company (BMY)

Return on assets (ROA)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	-8,948,000	8,025,000	6,327,000	6,994,000	-9,015,000
Total assets	US$ in thousands	92,603,000	95,159,000	96,820,000	109,314,000	118,481,000
ROA		-9.66%	8.43%	6.53%	6.40%	-7.61%

December 31, 2024 calculation

ROA = Net income ÷ Total assets
= $-8,948,000K ÷ $92,603,000K
= -9.66%

Based on the provided data, Bristol-Myers Squibb Company's return on assets (ROA) has exhibited significant fluctuations over the past five years.

- In December 2020, the ROA was negative, indicating that the company's assets did not generate a positive return during that period.
- However, the ROA improved considerably in the subsequent years, reaching 6.40% in December 2021 and further increasing to 6.53% in December 2022.
- The company's ROA experienced a notable surge to 8.43% in December 2023, reflecting a more profitable utilization of its assets.
- Nevertheless, the ROA saw a sharp decline to -9.66% by December 2024, signifying a negative return on assets, which may raise concerns about the company's asset management efficiency during that period.

Overall, the varying trends in Bristol-Myers Squibb Company's ROA highlight the importance of monitoring and analyzing this ratio over time to assess the company's performance in effectively generating profits from its assets.